Browsing by Author "Ince, Idris"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Publication A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia(Cig Media Group, 2021-08-10) Gemici, Aliihsan; Dogu, Mehmet Hilmi; Tekinalp, Atakan; Alacacioglu, Inci; Guney, Tekin; Ince, Idris; Geduk, Ayfer; Cağlıyan, Gulsum Akgun; Maral, Senem; Serin, Istemi; Gunduz, Eren; Karakus, Volkan; Bekoz, Huseyin Saffet; Eren, Rafet; Gunes, Ahmet Kursad; Sargin, Fatma Deniz; Sevindik, Omur Gokmen; Ozkalemkas, Fahir; ÖZKALEMKAŞ, FAHİR; Pinar, Ibrahim Ethem; PINAR, İBRAHİM ETHEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; JWP-2738-2024; AAA-5330-2022Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. (C) 2021 Elsevier Inc. All rights reserved.Publication Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in Turkey(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Soyer, Nur; Ali, Ridvan; Turgut, Mehmet; Haznedaroglu, Ibrahim C.; Yilmaz, Fergun; Aydogdu, Ismet; Karakus, Volkan; Ozgur, Gokhan; Kis, Cem; Ceran, Funda; Ilhan, Gul; Ozkan, Melda; Aslaner, Muzeyyen; Ince, Idris; Yavasoglu, Irfan; Gediz, Fusun; Sonmez, Mehmet; Guvenc, Birol; Ozet, Gulsum; Kaya, Emin; Vural, Filiz; Tobu, Mahmut; Durusoy, Raika; Pir, Ali; KAYA, PİR ALİ; Vural, Filiz; Şahin, Fahri; Saydam, Guray; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0001-5118-6894; 0000-0001-9178-2850; 0000-0001-7423-7180; 0000-0002-7798-4349; 0000-0001-6621-3138; 0000-0002-2176-4371; 0000-0001-8605-8497; 0000-0003-1041-8462; W-3827-2017; ABH-5764-2020; AAB-7711-2022; JYO-9281-2024; W-2951-2017; HRC-6282-2023; W-7916-2019; B-7408-2009; A-4238-2018Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.